Adaptive properties and heterogeneity of dopamine D2 receptors - Pharmacological implications

Brain Research Reviews

Volumn 58, Issue 2, 2008, Pages 374-378

  Carlsson, Arvid ^a   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Adaptive properties; Antipsychotic agents; Dopamine D2 receptors; Dopamine stabilizers; Heterogeneity; Neuropsychiatric disorders

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; AMISULPRIDE; BENZAMIDE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; REMOXIPRIDE; SYNAPSE RECEPTOR;

ADAPTATION; ANHEDONIA; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSPHORIA; DYSTONIA; HUMAN; MENTAL DISEASE; NEUROPHARMACOLOGY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIDE EFFECT;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; DOPAMINE AGENTS; HUMANS; NEURONAL PLASTICITY; RECEPTORS, DOPAMINE D2;

EID: 49449085844     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2007.09.007     Document Type: Review

References (34)

1. Arnt J., Bogeso K.P., Christensen A.V., Hyttel J., Larsen J.J., and Svendsen O. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacology (Berl.) 81 (1983) 199-207
2. 123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl.) 150 (2000) 132-140
3. Cai G., Wang H.Y., and Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 302 (2002) 1105-1112
4. Carlsson A. Dopaminergic autoreceptors. In: Almgren O., Carlsson A., and Engel J. (Eds). Chemical Tools in Catecholamine Research vol. II (1975), North-Holland Publishing Company, Amsterdam 219-229
5. Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of receptor. J. Neural Transm. 57 (1983) 309-315
6. Carlsson. M., 1988. Sex differences in monoaminergic mechanisms in rat. Thesis, University of Gothenburg, pp 1-41.
7. Carlsson M., and Eriksson E. The intrinsic activity of (-)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion. Life Sci. 42 (1988) 585-588
8. Carlsson M., and Eriksson E. The partial dopamine receptor agonists (-)-3-PPP and transdihydrolisuride enhance prolactin secretion in female but not in male rats. J Neural Transm. 77 (1989) 211-216
9. Carlsson A., and Carlsson M.L. Dopaminergic stabilisers. Adv. Schizophr. Clin. Psychiatry 1 (2005) 118-128
10. Carlsson M., Eriksson E., Nilsson C., and Carlsson A. Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion. Neuropharmacology 25 (1986) 951-954
11. Carlsson M., Carlsson A., and Eriksson E. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. Eur. J. Pharmacol. 142 (1987) 39-43
12. Carlsson M.L., Carlsson A., and Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem. 11 (2004) 267-277
13. 2L receptors. Neuropsychopharmacology 27 (2002) 723-726
14. Clark D., Hjorth S., and Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: I. Review of the evidence. J. Neural Transm. 62 (1985) 1-52
15. Clark D., Hjorth S., and Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: II. Theoretical considerations. J. Neural Transm. 62 (1985) 171-207
16. Descarries L., and Mechawar N. Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. In: Agnati L.F., Fuxe K., Nicholson C., and Sysková E. (Eds). Progress in Brain Research vol. 125 (2000), Elsevier Science BV, Amsterdam 27-47
17. 3H-monoamines from field stimulated rat brain slices. Acta Physiol. Scand., Suppl. 371 (1971) 35-44
18. 3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31 (2006) 1027-1035
19. 2 receptor ligand on l-DOPA-induced dyskinesias in MPTP monkeys. Eur. J. Pharmacol. 412 (2001) 247-254
20. Kehr W., Carlsson M., Lindqvist M., Magnusson T., and Atack C.V. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol. 24 (1972) 744-747
21. Lahti R.A., Tamminga C.A., and Carlsson A. Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D(2) receptor function in vitro. J. Neural Transm. (2007) (Jul 6 (on line))
22. Lewis D.A., Melchitzky D.S., Sesack S.R., Whitehead R.E., Auh S., and Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J. Comp. Neurol. 432 (2001) 119-136
23. 125I] 2′-iodospiperone. Psychopharmacology (Berl.) 110 (1993) 27-36
24. 3 receptors. Mol. Pharmacol. 43 (1993) 749-754
25. 2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J. Pharmacol. Exp. Ther. 318 (2006) 808-810
26. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell P.J., Costa D.C., and Kerwin R.W. Limbic selectivity of clozapine. Lancet 350 (1997) 490-491
27. Ross S.B. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J. Neurochem. 56 (1991) 22-29
28. Seeman P., and Guan H.C. Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur. J. Pharmacol. 557 (2007) 151-153
29. Sesack S.R. Synaptology of dopamine neurons. In: Di Chiara G. (Ed). Dopamine in the CNS I. Handbook Exper. Pharmacol. vol. 154/I (2002), Springer, Berlin 63-119
30. Sesack S.R., Hawrylak V., Matus C., Guido M.A., and Levey A.I. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J. Neurosci. 18 (1998) 2697-2708
31. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53 (2001) 119-133
32. Wu K., and Black I.B. Transsynaptic impulse activity regulates postsynaptic density molecules in developing and adult rat superior cervical ganglion. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 6207-6210
33. 2 dopamine receptor blockade by amisulpride in schizophrenia. J. Clin. Psychopharmacol. 21 (2001) 207-214
34. Zoli M., Jansson A., Sykova E., Agnati L.F., and Fuxe K. Volume transmission in the CNS and its relevance for neuropsychopharmacology. Trends Pharmacol. Sci. 20 (1999) 142-150